Special Issue

HPV in the Head and Neck Region 2.0

Message from the Guest Editors

There are more than 100 human papillomaviruses (HPVs), 13 of which are considered to be carcinogenic. Of those types, HPV 16 is associated with roughly 90% of HPV+ head and neck cancers, and the incidences of HPV+ tonsillar and base-of-tongue cancer have been increasing in many Western countries. Notably, HPV+ tonsillar and base of tongue cancer also have a considerably better prognosis than the corresponding HPV- tonsillar and base-of-tongue cancers. In addition, other HPV members can cause benign tumors of the head and neck region. In this Special Issue, we wish to explore current research in HPV in the head and neck region. Topics of interest include, but are not limited to, the following:

- The role of human papillomaviruses in cancer, benign tumors, and lesions in the head and neck region;
- Diagnosis of human papillomavirus in cancer of the head and neck region;
- Epidemics of human-papillomavirus-induced cancer in the head and neck region;
- Therapeutic approaches including immune responses and/or targeted therapy and biomarkers in humanpapillomavirus-positive cancer of the head and neck region;
- HPV vaccination and it's effects.

Guest Editors Prof. Dr. Tina Dalianis Prof. Dr. Christian von Buchwald Dr. Anders Näsman Prof. Dr. Stina Syrjänen

Deadline for manuscript submissions

closed (30 December 2022)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.8 CiteScore 7.3 Indexed in PubMed



mdpi.com/si/117648

Viruses MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/

viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.8 CiteScore 7.3 Indexed in PubMed



viruses



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.1 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2024).